

Journal für

Reproduktionsmedizin und Endokrinologie

– Journal of Reproductive Medicine and Endocrinology –

Andrologie • Embryologie & Biologie • Endokrinologie • Ethik & Recht • Genetik
Gynäkologie • Kontrazeption • Psychosomatik • Reproduktionsmedizin • Urologie



Foreword

J. Reproduktionsmed. Endokrinol 2015; 12 (4), 194-197

www.kup.at/repromedizin

Online-Datenbank mit Autoren- und Stichwortsuche

Offizielles Organ: AGRBM, BRZ, DVR, DGA, DGGEF, DGRM, D-I-R, EFA, OEGRM, SRBM/DGE

Indexed in EMBASE/Excerpta Medica/Scopus

Krause & Pachernegg GmbH, Verlag für Medizin und Wirtschaft, A-3003 Gablitz



ENDO FERTI FORUM

ENDOKRINOLOGIE & FERTILITÄT
FÜR KLINIK & PRAXIS

20.-21. März 2026

Universitätsmedizin Mainz

Einladung zu unserer wissenschaftlichen Veranstaltung Endo-Ferti-Forum

Brücke(n) zwischen Unikliniken und Praxen an Rhein und Main(z)

– die aus dem bisherigen Format „Ferti Forum“ ab 2026 hervorgeht –



Freuen Sie sich auf spannende Vorträge und den lebendigen Austausch mit Kolleg:innen und Expert:innen aus Klinik und Praxis. Freitagabend laden wir Sie herzlich zu einem entspannten Empfang ein – eine perfekte Gelegenheit, Kontakte zu knüpfen und den Tag genussvoll ausklingen zu lassen.

Wissenschaftliche Leitung: Univ.-Professorin Annette Hasenburg, Dr. Susanne Theis, Universitätsmedizin Mainz, Sanitätsrat Dr. Werner Harlfinger, BVF Rheinland-Pfalz Dr. Rüdiger Gaase, BVF Hessen Dr. Klaus J. Doubek

Schirmherrschaften: Prof. Nicole Sänger, Uniklinik Bonn, Prof. Jan-Steffen Krüssel, Uniklinik Düsseldorf, Dr. Annette Bachmann, Uniklinik Frankfurt am Main, Prof. Christine Skala, Uniklinik Köln

Weitere Informationen
& Anmeldung unter



Foreword – DVR-Representation



Hermann M. Behre
Chairman DVR e.V.
DGA e.V.



Thomas Rabe
DGGEF e.V.



Kaus Bühler
Deputy Chairman
DVR e.V.



Tina Buchholz
DGRM e.V.




Ullrich Hilland
BRZ e.V.



Ludwig Kiesel
SRBM/DGE e.V.



Thomas Katzorke
ADI e.V.



Frank-Michael Köhn
AAD/DDG e.V.



Jens Hirschhain
Secretary DVR e.V.
AGRBM e.V.



Ute Ceromin
DIR e.V.



Georg Wilke
Treasurer DVR e.V.

Egon Diczfalusy was born in Miskolc/Hungary on September 19th, 1920. He completed his medical studies at the University of Szeged/Hungary in 1944. From 1947 on he worked at the Karolinska University Hospital in Stockholm/Sweden. As a scientist, he discovered the fetoplacental unit, and showed that the steroidogenesis in pregnancy reflects the close interaction between the maternal and fetal metabolism within the placenta. More than 200 Fellows from around the world have conducted research with him and still form a closely linked network.

Later, he became chairman of the “Special Programme of Research in Human Reproduction,” of the WHO/Geneva/Switzerland, one of the oldest and best known research programs of the World Health Organisation. During his tenure at WHO, he helped to build international research networks and focused on the new development of new agents for birth control, but also for the treatment of infertility in Africa, Asia, Eastern Europe and South America. In addition to numerous honorary doctorates, hundreds of lectures and publications he has written the following books:

- Endocrine Mechanisms in Fertility Regulation: Comprehensive Endocrinology (1983)
- The demographic revolution (1999)
- Oestrogene beim Menschen (2012)

Egon Diczfalusy has always been a dedicated idealist who has supported the framework of humanitarian actions, scientists and scientific institutions in developing countries for the last 35 years.

He established
**“THE EGON AND ANN DICZFALUSY
 FOUNDATION”**

dedicated to:


Empathy, Science, Hope

For him medicine is
Medicine anchora salutis


The umbrella organization of reproductive biology and medicine (DVR e.V.) in Germany congratulates a pioneer of reproductive medicine – Professor Egon Diczfalusy – to his 95th birthday and wishes him good health and vitality to witness the continuation of his foundation and its activities in the future.

Thomas Rabe
Guest Editor

Hermann Behre
Chairman DVR e.V.



Giuseppe Benagiano
Honorary President
Geneva, Switzerland



Henry L. Gabelnick
Vice-President
Arlington, VA, USA



Ilpo Huhtaniemi
London, UK



Ferenc Bari
Szeged, Hungary



Britt-Marie Landgren
Stockholm, Sweden

Foreword – Egon and Ann Diczfalusy Foundation



Established in Szeged (Hungary) in 2007.

Why was the Foundation established in Szeged? Professor Egon Diczfalusy was born in 1920 in Hungary. He spent his youth in Szeged and his Alma Mater was the University of Szeged. Therefore, it was natural for him to choose the city of his youth as the seat of the Foundation.


Egon Diczfalusy became known worldwide for his outstanding achievement in the field of reproductive endocrinology. Until his retirement he headed the Reproductive Endocrinology Laboratory of the Karolinska Institutet in Stockholm, Sweden. This laboratory became part of the Swedish Medical Research council and was selected as a Research and Training centre of the World Health Organisation.

Egon Diczfalusy is a dedicated humanitarian and an idealist who spent 40 years of his life helping scientists and scientific institutions all over the Developing World.

Because of his background and of his generosity he decided that he also had to support his Alma Mater: He encouraged clinicians and researchers of the Szeged University to open themselves to the world and helped establishing scientific exchanges and collaboration in the Balkan countries. His initial aim was to establish links between researchers from more developed countries like Italy, Sweden, Germany and the USA with countries like Romania and Serbia.

To coronate this work, in 2007, he established The Egon and Ann Diczfalusy Foundation for the support of research in Reproductive Health. The Foundation is dedicated to maintain the legacy of Professor Egon Diczfalusy and his wife Ann.

Egon Diczfalusy is the scientist who discovered and characterised the feto-placental unit, demonstrating for the first time that steroidogenesis in pregnancy is the consequence of a close interaction between the maternal and fetal organism, via the placenta.



György Bártfai
President
Szeged, Hungary



Tihomir Vejnovic
Vice-President
Novi Sad, Serbia



Thomas Rabe
Heidelberg, Germany



György Thaler
Budapest, Hungary



David Archer
Norfolk, VA, USA



Ana Mitrovic Jovanovic
Belgrade, Serbia



Peter Koliba
Vresina, Czech Republic



Zuzana Nižnanská
Bratislava, Slovakia

He also played a key role in the development of United Nations Interagency Programme under the leadership of the World Health Organisation, The Special Programme of Research in Human Reproduction.

A major part of his contribution consisted in leading the establishment of international networks of research devoted to the development of new fertility regulating agents and to combating the plight of infertility.

Purpose of the Foundation

- Supporting scientific work conducted in the field of reproductive health, recognising scientific results achieved so far.
- Launching new research programmes.
- Supporting the exchange of junior scientists.
- Promoting and supporting lectures and publications on the subject of reproductive health, and organising scientific events.
- Granting yearly the Diczfalusy Award, to acknowledge the scientific work carried out by a basic or a clinical scientist and her/his life-time scientific achievements.
- Presenting, also on a yearly basis, the Diczfalusy Medal to a researcher under the age of 40, working in the above-mentioned field.


This year, the 9th Diczfalusy Award Lecture Symposium is taking place in Novi Sad, Serbia. Hopefully this conference will be as successful as the previous ones and give an excellent opportunity to young researchers and clinicians from 3-state-area to obtain updated scientific information on the hot topics in Obstetrics and Gynaecology. The congress in this autumn will be a unique one because we celebrate Professor Egon Diczfalusy's 95th birthday.

This Conference is jointly organised with the newly established German-Serbian Gynaecologic Society and has a strong support from the Serbia-Montenegro Society of Gynaecology and Obstetrics. The Conference also enjoys full support from the University of Novi Sad and the Municipality of the city.

The multicultural atmosphere – Serbian, Hungarian, German, Romanian heritage – and the outstanding cultural life of Novi Sad and Vojvodina will provide an excellent milieu to strengthen the collaboration and friendship among young clinicians and researchers all over Europe.

György Bartfai
President

Guisepppe Benagiano
Honoray President



Petru Chitulea
Oradea, Romania



Eric Cosmi
Padua, Italy



Gábor Németh
Szeged, Hungary



Gyula Telegdy
Internal Scientific Advisory
Committee (ISAC)
Szeged, Hungary

Foreword – Gedeon Richter

Serving women since 1901

Headquartered in Hungary, Gedeon Richter Plc is a European specialty pharmaceutical company built on innovation. The company is more than 110 years old. In addition to pharmaceutical manufacturing, its activities include research and development, trade and marketing. Richter sells its products through its own marketing network in nearly 100 countries. The company's sales revenue exceeded 1.1 billion euros in 2014, and 36% of this was provided by its comprehensive range of gynaecological products.



World-class hormonal contraception

Gedeon Richter has been manufacturing gynaecological products since it was founded in 1901. Recognising the promise of organotherapy, a new therapeutic modality emerging at the turn of the 20th century, the founder, pharmacist Gedeon Richter, used his own proprietary procedure for the commercial manufacture of the natural adrenaline-based hormonal preparation, Tonogen supranale, which established his reputation. In 1902, Mr Richter formulated two additional preparations containing endocrine hormones: *Tabletta Ovarii* and *Tabletta Thyreoideae*. He later marketed his medications containing extracts of various endocrine glands under the brand name Hormogland. At the end of the 1930s, there were more than 60 Hormogland preparations on the market in addition to about 100 conventional organo-therapeutic medications. The technology



for isolating estrone was of fundamental significance; the industrial production of the crystalline version of estrone began at the beginning of the 1930s. This milestone coincided with the start of the research and development phase of the production of semi-synthetic steroids aimed at synthesising progesterone and testosterone from cholesterol. The 1950s saw the production of the key compound in hormone synthesis, which was used to produce sex hormones (progesterone, estrone, and testosterone), non-steroidal anabolic agents and oral contraceptives.

Starting at the beginning of the 1960s, the company introduced modern production technologies including sterile fermentation technology. The new technology introduced in 1972 made it possible to produce new active substances like norgestrel, levonorgestrel and their derivatives. Steroid R&D carried out during this era resulted in the development of a revolutionary, combined hormonal contraceptive, which first appeared in 1966 under the name of Infecundin tablets. Gedeon Richter was the first company to market a contraceptive product of this kind in Eastern Europe. The second-generation combination product Bisecurin, containing lower levels of the active substances, was a sign of the company's remarkable development. In 1981, the company was already using a closed production line for hormonal tablet manufacturing as the group of steroids and related products continued to gain ground in both production and marketing.

On the basis of valuable experience gained from manufacturing hormones, the company now has a world-class ste-



roid chemistry knowledge base. Thanks to the many developments, the company has one of the most extensive gynaecological portfolios, including the most advanced contraceptives, emergency contraceptives, hormone replacement and anti-infective agents. The product range, which serves the needs of all age groups, was expanded with a new preparation in 2012. Since then ulipristal, an innovative drug which has received reimbursement status in countless countries has been offering patients an unparalleled opportunity to treat uterine fibroids and even giving them a chance to avoid surgery.

The continuous geographical expansion of its gynaecological division (Western Europe, China and Latin America in addition to the traditional markets), its original research capacity and its century of manufacturing experience have made Richter a global player in gynaecological pharmaceutical products.

We are proud that in the past 114 years we have helped to treat millions of women and contributed to improving their quality of life.

We would like to take this opportunity to express our heartfelt gratitude to world-renowned expert in obstetrics and gynaecology, Prof. Egon Diczfalusy on the occasion of his 95th birthday. His commitment and professional achievements in the area of women's health protection are exemplary.

Erik Bogtsch
Managing Director
Gedeon Richter Plc.

Mitteilungen aus der Redaktion

Besuchen Sie unsere Rubrik

☒ Medizintechnik-Produkte



Neues CRT-D Implantat
Intica 7 HF-T QP von Biotronik



Artis pheno
Siemens Healthcare Diagnostics GmbH



Philips Azurion:
Innovative Bildgebungslösung

Aspirator 3
Labotect GmbH



InControl 1050
Labotect GmbH

e-Journal-Abo

Beziehen Sie die elektronischen Ausgaben dieser Zeitschrift hier.

Die Lieferung umfasst 4–5 Ausgaben pro Jahr zzgl. allfälliger Sonderhefte.

Unsere e-Journale stehen als PDF-Datei zur Verfügung und sind auf den meisten der marktüblichen e-Book-Readern, Tablets sowie auf iPad funktionsfähig.

☒ Bestellung e-Journal-Abo

Haftungsausschluss

Die in unseren Webseiten publizierten Informationen richten sich **ausschließlich an geprüfte und autorisierte medizinische Berufsgruppen** und entbinden nicht von der ärztlichen Sorgfaltspflicht sowie von einer ausführlichen Patientenaufklärung über therapeutische Optionen und deren Wirkungen bzw. Nebenwirkungen. Die entsprechenden Angaben werden von den Autoren mit der größten Sorgfalt recherchiert und zusammengestellt. Die angegebenen Dosierungen sind im Einzelfall anhand der Fachinformationen zu überprüfen. Weder die Autoren, noch die tragenden Gesellschaften noch der Verlag übernehmen irgendwelche Haftungsansprüche.

Bitte beachten Sie auch diese Seiten:

[Impressum](#)

[Disclaimers & Copyright](#)

[Datenschutzerklärung](#)